What organisms does Bactroban (mupirocin) cover?

What Organisms Does Bactroban (Mupirocin) Cover?

Bactroban (mupirocin) primarily covers Gram-positive bacteria, with excellent activity against Staphylococcus aureus (including methicillin-resistant strains, MRSA) and Streptococcus pyogenes, while having limited activity against most Gram-negative organisms. 1

Primary Coverage: Gram-Positive Bacteria

Staphylococcus species:

• Staphylococcus aureus (including MRSA) - This is mupirocin's primary target, with MICs ≤0.5 mcg/mL for nearly all clinical isolates 2
• Staphylococcus epidermidis - Active against most strains 1
• Staphylococcus saprophyticus - Active against most strains 1

Streptococcus species:

• Streptococcus pyogenes (Group A Streptococcus) - Highly susceptible 1, 3
• Most other streptococci 3

Limited Gram-Negative Coverage

Mupirocin has moderate activity against certain Gram-negative bacteria 3:

• Haemophilus influenzae 2, 4
• Neisseria gonorrhoeae 2, 4

However, mupirocin is much less active against most Gram-negative bacilli and anaerobes 2. This limited Gram-negative spectrum is clinically significant—mupirocin should not be relied upon for infections where Gram-negative organisms are suspected.

Clinical Applications Based on Coverage

FDA-approved indications 1:

• Impetigo (caused by S. aureus and S. pyogenes) 5
• Secondary skin infections

Guideline-supported uses 5, 6:

• Topical treatment: Mupirocin is the best topical agent for impetigo (Class A-I recommendation) 5
• Nasal decolonization: Intranasal mupirocin 2% effectively eliminates nasal carriage of both MSSA and MRSA, achieving >95% eradication rates 7, 8

Important Caveats

Resistance considerations:

• High-level plasmid-mediated resistance (MIC >1024 mcg/mL) has been reported in some staphylococcal strains 1
• Resistance appears to result from production of modified isoleucyl-tRNA synthetase 1
• No cross-resistance with other antibiotic classes due to unique mechanism of action 1, 2

Protein binding effects:

• Mupirocin is highly protein bound (>97%) 1
• Activity is reduced 10- to 20-fold in the presence of human serum 2
• The effect of wound secretions on MICs has not been determined 1

Bactericidal characteristics:

• MBCs are 8- to 32-fold higher than MICs 2
• Demonstrates slow bactericidal action, achieving 90-99% killing after 24 hours 2

The narrow but potent spectrum against staphylococci and streptococci makes mupirocin ideal for targeted therapy of superficial skin infections and staphylococcal decolonization, but it should not be used empirically when broader coverage is needed.